# US 10,118,891 B2 · Organosulfur compounds for the prevention and treatment of neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,118,891 B2
- Document ID: US10118891B2
- Status: Granted
- Kind: B2
- Application number: 15/530,804
- Filed: 2017-03-01
- Published: 2017-06-22
- Granted: 2018-11-06
- Earliest claimed: 2011-12-05
- Assignees: Allium Vitalis Incorporated
- Applicants: David Michael Ott
- Inventors: David Michael Ott
- Web page: https://patentgrep.com/patent/US10118891B2

## CPC

- C07C 323/59: with acylated amino groups bound to the carbon skeleton
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Organosulfur compounds and compositions are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein aggregates, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compositions include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, traumatic brain injury, stroke and cerebral ischemia.

## Claims

### Claim 1

The medicinal compound S-(3-((2-acetamido-2-carboxyethyl)-disulfanyl)propyl)-N-acetylcysteine or salts thereof.

### Claim 2

The medicinal compound S-(1-((2-acetamido-2-carboxyethyl)-disulfanyl)propan-2-yl)-N-acetylcysteine or salts thereof.

### Claim 3 (depends on 1, 2)

A medicinal composition comprising the compound of claim 1 and the compound of claim 2 or salts thereof.

### Claim 4 (depends on 3)

The medicinal composition of claim 3 where said salt is a salt of magnesium or calcium.

### Claim 5 (depends on 3)

A dietary supplement comprising the composition of claim 3.

### Claim 6 (depends on 3)

A nutraceutical comprising the composition of claim 3.

### Claim 7 (depends on 3)

A method of decreasing the amount of protein carbonyls within the central nervous system of an animal that has traumatic brain injury, said method comprising: administering to an animal in need thereof the medicinal composition of claim 3; said medicinal composition metabolizing during digestion to form allyl mercaptan; wherein said allyl mercaptan reacts with an aldehyde within the lipid membranes of said animal, said aldehyde being in the form of an aldehyde or in the form of a protein-aldehyde adduct, to produce a molecular conjugate of said allyl mercaptan and said aldehyde; thereby decreasing the neurotoxicity of said aldehyde.

### Claim 8 (depends on 7)

The method of claim 7 where said administration of said medicinal composition produces a decrease in the amount of protein carbonyls within the frontal cortex region of the brain.

### Claim 9 (depends on 7)

The method of claim 7 where said administration of said medicinal composition produces a decrease in the amount of protein carbonyls within the substantia nigra region of the brain.

### Claim 10 (depends on 7)

The method of claim 7 where said medicinal composition is administered orally in an amount within the range of 5 mg to 2,000 mg per day.

### Claim 11 (depends on 10)

The method of claim 10 where said medicinal composition is a dietary supplement.

### Claim 12 (depends on 10)

The method of claim 10 where said medicinal composition is a nutraceutical.

### Claim 13 (depends on 7)

The method of claim 7 where said traumatic brain injury is the result of concussion from a sports injury.

### Claim 14 (depends on 7)

The method of claim 7 where said traumatic brain injury is the result of concussion from an accident involving a vehicle.

### Claim 15 (depends on 7)

The method of claim 7 where said traumatic brain injury is the result of concussion from an explosion.